Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study
Dermatology and Therapy · 2026-06 · 16 (6) · 3167-3188
DOI: 10.1007/s13555-026-01772-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatology and Therapy, online erschienen am 10.05.2026. Verfasst von Toshiyuki Yamamoto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Fukushima Medical University, Fukushima, Japan. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie GK.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Fukushima Medical University, Fukushima, Japan.
- Department of Dermatology, Kansai Medical University, Hirakata, Japan.
- Department of Dermatology, Tohoku University, Sendai, Japan.
- ALOOP CLINIC and LAB, Tokyo, Japan.
- Medical, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo, 108-0023, Japan. naoko.matsubara@abbvie.com.
- Medical, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo, 108-0023, Japan.
Förderung
- AbbVie GK
Zitieren
APA
Yamamoto, T., Tanizaki, H., Yamasaki, K., Matsubara, N., Nakayama, M., Iwashita, E., & Yamanaka, K. (2026). Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study. Dermatology and Therapy, 16(6), 3167-3188. https://doi.org/10.1007/s13555-026-01772-4
Vancouver
Yamamoto T, Tanizaki H, Yamasaki K, Matsubara N, Nakayama M, Iwashita E, et al. Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study. Dermatology and Therapy. 2026;16(6):3167-3188. doi:10.1007/s13555-026-01772-4
BibTeX
@article{Yamamoto2026,
author = {Yamamoto, Toshiyuki and Tanizaki, Hideaki and Yamasaki, Kenshi and Matsubara, Naoko and Nakayama, Masahiko and Iwashita, Eri and Yamanaka, Keiichi},
title = {Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study},
journal = {Dermatology and Therapy},
year = {2026},
volume = {16},
number = {6},
pages = {3167--3188},
doi = {10.1007/s13555-026-01772-4}
}
EUVIMED